ChromaDex Co. (NASDAQ:CDXC - Get Free Report) Director Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
ChromaDex Stock Down 4.1 %
Shares of CDXC stock opened at $6.12 on Friday. The business's fifty day moving average is $5.66 and its 200 day moving average is $3.97. The stock has a market cap of $467.45 million, a price-to-earnings ratio of 612.61 and a beta of 2.16. ChromaDex Co. has a twelve month low of $1.32 and a twelve month high of $7.97.
ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the business earned ($0.01) EPS. Equities research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.
Analyst Ratings Changes
Is Starlink Set For The Largest IPO In History?
From Paradigm Press | Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant.
Then, he did it again with Tesla… which is up more than 19,500% since 2010.
For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
Several equities analysts have recently issued reports on the company. StockNews.com raised ChromaDex from a "buy" rating to a "strong-buy" rating in a research note on Monday, December 9th. HC Wainwright lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Monday, November 4th. Finally, Roth Mkm upped their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th.
View Our Latest Stock Analysis on CDXC
Institutional Trading of ChromaDex
Hedge funds have recently made changes to their positions in the stock. Miracle Mile Advisors LLC purchased a new position in ChromaDex during the second quarter valued at $27,000. The Manufacturers Life Insurance Company bought a new position in shares of ChromaDex during the second quarter valued at $31,000. Merriman Wealth Management LLC purchased a new position in shares of ChromaDex in the 2nd quarter worth about $32,000. FMR LLC bought a new position in ChromaDex in the 3rd quarter worth about $55,000. Finally, Marshall Wace LLP purchased a new stake in ChromaDex during the 2nd quarter valued at about $56,000. 15.41% of the stock is owned by institutional investors.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
